Merck & Co. v. Reynolds
The Court ruled that a securities fraud lawsuit against Merck over Vioxx was filed on time, because the two-year deadline for suing doesn't start until investors actually discover, or a reasonably careful investor would have discovered, facts showing the company acted with intent to deceive.
The decision clarifies a nationwide split among lower courts over how to read the discovery-based deadline Congress wrote for securities fraud suits, holding that mere warning signs of possible wrongdoing aren't enough to start the clock until facts about the company's fraudulent state of mind come to light.
How it got here: A federal trial court dismissed the suit as too late; the Third Circuit reversed and found it timely; Merck asked the Supreme Court to resolve a circuit split.
The Case in Depth
What happened
Investors sued Merck & Co., claiming the company knowingly hid the heart attack risks of its painkiller Vioxx, causing them financial losses when the risks became public. Before the lawsuit, a 2000 study linked Vioxx to more heart attacks than a rival drug, the FDA later criticized Merck's marketing as misleading, and product-liability suits accused Merck of concealing risk information.
The question before the Court
Does the clock for filing a securities fraud lawsuit start only once investors actually discovered, or reasonably should have discovered, facts showing intent to deceive?
The Court's answer
Partly — the Court sided with the investors, ruling their fraud suit against Merck was filed on time. The two-year deadline for these lawsuits doesn't start until an investor actually learns, or a reasonably careful investor would have learned, facts showing the company acted with intent to deceive — not merely facts suggesting something might be wrong.
Because the pre-2001 warning signs about Vioxx (a troubling study, an FDA letter, and product-liability complaints) showed only that Merck's marketing might have been misleading, not that Merck knowingly lied, those facts weren't enough to start the clock. Since the deadline hadn't run when investors sued, their case can proceed.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Investors who suspect a company misled them about a product's risks get more time to build a fraud case, since the filing deadline doesn't start ticking until evidence of intentional deception surfaces, not just evidence that something might be wrong. Companies facing shareholder fraud suits can no longer rely on early warning signs alone to argue a lawsuit came too late.
What changes now
The Supreme Court's ruling affirms that the investors' lawsuit was filed on time, so the case returns to the ordinary litigation track in the lower courts to be decided on the merits of whether Merck actually committed securities fraud. The Court did not decide whether a later 2003 study might separately have started the clock, since that question wasn't necessary to resolve timeliness here.
What this does not decide
The Court did not decide what other facts (such as reliance, financial loss, or loss causation) must be discovered to start the clock, nor whether a 2003 Brigham and Women's Hospital study might independently have triggered the deadline. Those questions were left open for other cases.
Concurrences and dissents
Concurrence in part — Justice Stevens
Justice Stevens agreed the suit was timely but said much of the majority's lengthy discussion of whether 'discovery' means only actual discovery or also includes constructive discovery was unnecessary here, since the two would have produced the same result in this case. He would wait for a case where the distinction actually matters before resolving Justice Scalia's argument.
Concurrence in part — Justice Scalia
Justice Scalia, joined by Justice Thomas, agreed the suit was timely and that scienter must be discovered, but argued the deadline should run only from actual discovery, not from when a reasonably diligent investor should have discovered fraud. He reasoned that Congress's choice not to include the 'reasonable diligence' language used in a related securities statute showed it meant only actual discovery here.
How the Court got there
The legal reasoning, step by step
- The Court read the word 'discovery' in the securities-fraud filing deadline as invoking the long-standing 'discovery rule,' under which a legal claim doesn't start its clock until the plaintiff actually learns of it or a reasonably careful plaintiff would have learned of it — whichever comes first.
- The Court found that Congress, in writing this deadline in 2002, copied language from an earlier case interpreting a similar securities provision, and courts had consistently read that earlier language to include this same reasonably-diligent-plaintiff standard, so Congress is presumed to have adopted that established meaning.
- The Court held that the 'facts constituting the violation' that must be discovered include facts showing scienter — the company's intent to deceive — because proving intentional wrongdoing, not just an innocent mistake, is a required element of this type of fraud claim.
- The Court rejected Merck's argument that facts showing a statement was false automatically show intent to deceive, reasoning that in securities cases a false or overly rosy statement can just as easily reflect an honest mistake as intentional fraud.
- The Court also rejected using 'inquiry notice' — the point where a reasonable investor would start looking into a problem — as the trigger date, because the statute only starts the clock once facts revealing fraud are actually or hypothetically discovered, not merely once investigation is warranted.
- Applying this standard to the record, the Court concluded that the FDA's 2001 warning letter and product-liability lawsuits raised concerns about Merck's marketing but did not reveal facts showing Merck deliberately lied, so the relevant facts were not discoverable before the cutoff date.
Doctrinal impact
Cases affected by this decision
Reaffirms Lampf, Pleva, Lipkind, Prupis & Petigrow v. Gilbertson (501 U. S. 350)
The Court relied on Lampf's earlier choice of 'discovery' language as the basis for interpreting the new deadline statute.